Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection
Phase of Trial: Phase 0
Latest Information Update: 29 Sep 2017
Price : $35 *
At a glance
- Drugs Cetuximab (Primary) ; Hyaluronidase (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 24 Oct 2016 Status changed from recruiting to completed.
- 12 Aug 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017.
- 18 Jan 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov